Anti-malarial Drugs Market Product Analysis and Forecast 2020-2025 | Top Vendors: Merck, F. Hoffmann-La Roche, Novartis, GSK, Ranbaxy, Zydus Cadila, Alvizia, Bayer, Pfizer, Ipca Laboratories

The report on Global Anti-malarial Drugs Market 2020 includes a study of annual and financial reports of top players, Market Share and Market Size. This research report offers in-depth study of Key Players, Product and Regional Analysis over the forecast period (2020-2025).

Global Anti-malarial Drugs Market overview:

Antimalarial medication is used to prevent and treat malaria. One should always consider taking antimalarial medicine when travelling to areas where there's a risk of malaria. Malaria is caused by a parasite known as Plasmodium, which is normally spread through infected mosquitoes. A mosquito takes a blood meal from an infected human, taking in Plasmodia which are in the blood. The Global Anti-malarial Drugs Market is segmented on the basis of Product Type, Application, End Use Industry and Region. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/280070 .

On the Basis of Product Type segment, the Anti-malarial Drugs Market is sub segmented into Quinine, Chloroquine, Pyrimethamine, Amodiaquine, Proguanil, Mefloquine, Sulfonamide and Other. Based on End Use Industry segment, the Anti-malarial Drugs Market is segmented as Falciparum Malaria, Vivax Malaria and Others.

There are several manufacturers of Anti-malarial Drugs in Europe and North America. In North America, the demand for Anti-malarial Drugs is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Anti-malarial Drugs Market Report 2020” @ https://www.businessindustryreports.com/buy-now/280070/single .

Top Industry News:

Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine on 20 October, 2020 -- Merck, known as MSD outside the United States and Canada, today announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. In the PNEU-PATH (V114-016) study, healthy adults 50 years of age or older received V114 or PCV13 followed by PNEUMOVAX® 23 one year later. Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results also showed that at 30 days post vaccination with either V114 or PCV13 (day 30), immune responses were comparable for both groups across the 13 serotypes shared by the conjugate vaccines and higher in the V114 group for serotypes 22F and 33F, the two serotypes not included in PCV13. In PNEU-DAY (V114-017), a Phase 3 study in immunocompetent adults 18 to 49 years of age with underlying medical conditions associated with increased risk for pneumococcal disease, V114 generated immune responses generally comparable to PCV13 for the 13 shared serotypes and higher immune responses for serotypes 22F and 33F at 30 days post-vaccination. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. V114 was generally well tolerated in both studies, with a safety profile consistent with that observed for V114 in previously reported studies.

“Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “These data provide important information about the potential for V114 followed by PNEUMOVAX 23, a polysaccharide vaccine included in more than 90 percent of age-based adult pneumococcal immunization programs globally, to help protect healthy adults and adults who are at increased risk for pneumococcal disease.”

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/280070 .

Major Key Players:

Some of the Anti-malarial Drugs Market manufacturers involved in the market are Merck KGaA, F. Hoffmann-La Roche AG, Novartis AG, GlaxoSmithKline Plc, Ranbaxy Laboratories, Zydus Cadila, Alvizia Health Care, Bayer AG, Pfizer Inc., Ipca Laboratories Ltd in World, effective mergers are some of the strategies adopted by the Anti-malarial Drugs Market manufacturers. New product launches and continuous technological innovations are the Anti-malarial Drugs Market strategies adopted by the major players.

Table of Contents:

1 Anti-malarial Drugs Product Definition
2 Global Anti-malarial Drugs Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Anti-malarial Drugs Shipments
2.2 Global Manufacturer Anti-malarial Drugs Business Revenue
2.3 Global Anti-malarial Drugs Market Overview
3 Manufacturer Anti-malarial Drugs Business Introduction
3.1 Merck KGaA Anti-malarial Drugs Business Introduction
3.1.1 Merck KGaA Anti-malarial Drugs Shipments, Price, Revenue and Gross profit 2020-2025
3.1.2 Merck KGaA Anti-malarial Drugs Business Distribution by Region
3.1.3 Merck KGaA Interview Record
3.1.4 Merck KGaA Anti-malarial Drugs Business Profile
3.1.5 Merck KGaA Anti-malarial Drugs Product Specification
3.2 F. Hoffmann-La Roche AG Anti-malarial Drugs Business Introduction
3.2.1 F. Hoffmann-La Roche AG Anti-malarial Drugs Shipments, Price, Revenue and Gross profit 2020-2025
3.2.2 F. Hoffmann-La Roche AG Anti-malarial Drugs Business Distribution by Region
3.2.3 Interview Record
3.2.4 F. Hoffmann-La Roche AG Anti-malarial Drugs Business Overview
3.2.5 F. Hoffmann-La Roche AG Anti-malarial Drugs Product Specification
3.3 NOVARTIS AG Anti-malarial Drugs Business Introduction
3.3.1 NOVARTIS AG Anti-malarial Drugs Shipments, Price, Revenue and Gross profit 2020-2025
3.3.2 NOVARTIS AG Anti-malarial Drugs Business Distribution by Region
3.3.3 Interview Record
3.3.4 NOVARTIS AG Anti-malarial Drugs Business Overview
3.3.5 NOVARTIS AG Anti-malarial Drugs Product Specification
3.4 GlaxoSmithKline Plc Anti-malarial Drugs Business Introduction
3.5 Ranbaxy Laboratories Anti-malarial Drugs Business Introduction
3.6 Zydus Cadila Anti-malarial Drugs Business Introduction
……

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.